Susquehanna Fundamental Investments LLC Takes $1 Million Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Susquehanna Fundamental Investments LLC acquired a new position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 213,213 shares of the company's stock, valued at approximately $1,002,000. Susquehanna Fundamental Investments LLC owned 0.40% of Fulcrum Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its holdings in Fulcrum Therapeutics by 2.3% in the fourth quarter. Bank of New York Mellon Corp now owns 141,873 shares of the company's stock valued at $667,000 after purchasing an additional 3,126 shares during the last quarter. American Century Companies Inc. grew its position in shares of Fulcrum Therapeutics by 5.9% during the 4th quarter. American Century Companies Inc. now owns 120,611 shares of the company's stock worth $567,000 after buying an additional 6,770 shares during the period. Wells Fargo & Company MN increased its stake in shares of Fulcrum Therapeutics by 34.4% in the 4th quarter. Wells Fargo & Company MN now owns 34,264 shares of the company's stock valued at $161,000 after acquiring an additional 8,761 shares during the last quarter. Intech Investment Management LLC raised its position in shares of Fulcrum Therapeutics by 74.9% in the 4th quarter. Intech Investment Management LLC now owns 30,499 shares of the company's stock valued at $143,000 after acquiring an additional 13,057 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Fulcrum Therapeutics by 1.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,320,862 shares of the company's stock valued at $4,716,000 after buying an additional 13,485 shares during the period. 89.83% of the stock is owned by institutional investors.

Fulcrum Therapeutics Price Performance

NASDAQ:FULC traded up $1.24 during trading hours on Friday, reaching $5.62. 4,174,620 shares of the stock were exchanged, compared to its average volume of 961,385. The stock has a market cap of $303.36 million, a PE ratio of -18.13 and a beta of 2.29. Fulcrum Therapeutics, Inc. has a twelve month low of $2.32 and a twelve month high of $10.13. The firm has a 50 day moving average of $3.18 and a 200 day moving average of $3.63.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.01. Equities research analysts anticipate that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a "neutral" rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a research note on Wednesday, February 26th. One analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $8.63.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.